Kang B, Murphy M, Ng C, Leventhal M, Huynh N, Im E
bioRxiv. 2025; .
PMID: 40027702
PMC: 11870572.
DOI: 10.1101/2025.02.19.639023.
Landles C, Osborne G, Phillips J, Canibano-Pico M, Nita I, Ali N
Brain Commun. 2024; 6(6):fcae410.
PMID: 39713241
PMC: 11660907.
DOI: 10.1093/braincomms/fcae410.
Mathews E, Coffey S, Gartner A, Belgrad J, Bragg R, OReilly D
bioRxiv. 2024; .
PMID: 39574582
PMC: 11580907.
DOI: 10.1101/2024.11.04.619693.
Feleus S, Skotnicki L, Roos R, de Bot S
Mov Disord Clin Pract. 2024; 11(12):1530-1541.
PMID: 39431460
PMC: 11647978.
DOI: 10.1002/mdc3.14230.
Jordi L, Isacson O
Prog Neurobiol. 2024; 242:102673.
PMID: 39389338
PMC: 11809673.
DOI: 10.1016/j.pneurobio.2024.102673.
Protein modification in neurodegenerative diseases.
Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A
MedComm (2020). 2024; 5(8):e674.
PMID: 39105197
PMC: 11298556.
DOI: 10.1002/mco2.674.
Why Is Arginine the Only Amino Acid That Inhibits Polyglutamine Monomers from Taking on Toxic Conformations?.
Tanimoto S, Okumura H
ACS Chem Neurosci. 2024; 15(15):2925-2935.
PMID: 39009034
PMC: 11311134.
DOI: 10.1021/acschemneuro.4c00276.
Protective Proteolysis in Huntington's Disease: Unraveling the Role of Post-Translational Myristoylation of Huntingtin in Autophagy.
Alshehabi Y, Martin D
J Huntingtons Dis. 2024; 13(3):267-277.
PMID: 38995796
PMC: 11492065.
DOI: 10.3233/JHD-240028.
Sex contribution to average age at onset of Huntington's disease depends on the number of (CAG) repeats.
Stanislawska-Sachadyn A, Krzeminski M, Zielonka D, Krygier M, Zietkiewicz E, Slawek J
Sci Rep. 2024; 14(1):15729.
PMID: 38977715
PMC: 11231309.
DOI: 10.1038/s41598-024-64105-5.
Making Sense of Censored Covariates: Statistical Methods for Studies of Huntington's Disease.
Lotspeich S, Ashner M, Vazquez J, Richardson B, Grosser K, Bodek B
Annu Rev Stat Appl. 2024; 11:255-277.
PMID: 38962579
PMC: 11220439.
DOI: 10.1146/annurev-statistics-040522-095944.
Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
Choi D, Shin J, Zeng S, Hong E, Jang J, Loupe J
Elife. 2024; 12.
PMID: 38869243
PMC: 11175616.
DOI: 10.7554/eLife.89782.
Transient interdomain interactions modulate the monomeric structural ensemble and self-assembly of Huntingtin Exon 1.
Mohanty P, Phan T, Mittal J
bioRxiv. 2024; .
PMID: 38766024
PMC: 11100600.
DOI: 10.1101/2024.05.03.592468.
Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications.
Mani Giri P, Banerjee A, Ghosal A, Layek B
Int J Mol Sci. 2024; 25(7).
PMID: 38612804
PMC: 11011898.
DOI: 10.3390/ijms25073995.
Targeting -Methyl-d-Aspartate Receptors in Neurodegenerative Diseases.
Carles A, Freyssin A, Perin-Dureau F, Rubinstenn G, Maurice T
Int J Mol Sci. 2024; 25(7).
PMID: 38612544
PMC: 11011887.
DOI: 10.3390/ijms25073733.
Posttranscriptional regulation of by miR-124-3p at rs3512 underlies onset-delaying genetic modification in Huntington's disease.
Kim K, Hong E, Lee Y, McLean Z, Elezi E, Lee R
Proc Natl Acad Sci U S A. 2024; 121(16):e2322924121.
PMID: 38607933
PMC: 11032436.
DOI: 10.1073/pnas.2322924121.
Somatic and intergenerational G4C2 hexanucleotide repeat instability in a human C9orf72 knock-in mouse model.
Kojak N, Kuno J, Fittipaldi K, Khan A, Wenger D, Glasser M
Nucleic Acids Res. 2024; 52(10):5732-5755.
PMID: 38597682
PMC: 11162798.
DOI: 10.1093/nar/gkae250.
Modification of Huntington's disease by short tandem repeats.
Hong E, Ramos E, Aziz N, Massey T, McAllister B, Lobanov S
Brain Commun. 2024; 6(2):fcae016.
PMID: 38449714
PMC: 10917446.
DOI: 10.1093/braincomms/fcae016.
Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype.
Ruiz de Sabando A, Ciosi M, Galbete A, Cumming S, Monckton D, Ramos-Arroyo M
Eur J Hum Genet. 2024; 32(7):770-778.
PMID: 38433266
PMC: 11220145.
DOI: 10.1038/s41431-024-01546-6.
A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
Aldous S, Smith E, Landles C, Osborne G, Canibano-Pico M, Nita I
Brain. 2024; 147(5):1784-1798.
PMID: 38387080
PMC: 11068328.
DOI: 10.1093/brain/awae063.
Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease.
Bondulich M, Phillips J, Canibano-Pico M, Nita I, Byrne L, Wild E
Brain Commun. 2024; 6(1):fcae030.
PMID: 38370446
PMC: 10873584.
DOI: 10.1093/braincomms/fcae030.